Treatment of Low-Risk Basal Cell Carcinoma

Nicole W. J. Kelleners-Smeets*, Klara Mosterd, Patty J. Nelemans

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

15 Downloads (Pure)

Abstract

With the continuously rising incidence and changing populations of patients with basal cell carcinoma, evidence about the different treatment modalities is mandatory. Randomized clinical trials, such as the surgery versus imiquimod for nodular superficial basal cell carcinoma trial, can provide this evidence. Patients can then be informed about all aspects of alternative treatment options so that conscious, shared decisions can be made.

Original languageEnglish
Pages (from-to)539-540
Number of pages2
JournalJournal of Investigative Dermatology
Volume137
Issue number3
DOIs
Publication statusPublished - Mar 2017

Keywords

  • RANDOMIZED CONTROLLED-TRIAL
  • GENERAL-PRACTITIONERS

Fingerprint

Dive into the research topics of 'Treatment of Low-Risk Basal Cell Carcinoma'. Together they form a unique fingerprint.

Cite this